Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
49 hedge funds and large institutions have $306M invested in Forte Biosciences in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 7 reducing their positions, and 13 closing their positions.
278% more capital inflows, than outflows
Capital inflows: $79.7M | Capital outflows: $21.1M
171% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 7
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
4.72% more ownership
Funds ownership: 60.7% → 65.41% (+4.7%)
4% more funds holding
Funds holding: 47 → 49 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$13.2M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$12.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$10.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.34M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.59M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.21M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.5M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.05M |
FBRX Hedge Fund Activity: Q4 2020 in Review
49 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2020, worth a combined $306M — down 7.4% from $330M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new FBRX positions and 13 closed out — a net gain of 2 holders — while 19 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $13.2M. The largest seller was OrbiMed, cutting an estimated $9.34M.
- 49 institutional investors held Forte Biosciences (FBRX) as of Q4 2020, up from 47 in Q3 2020.
- Funds reported $306M of Forte Biosciences stock for Q4 2020, down 7.4% quarter-over-quarter.
- 15 funds opened new Forte Biosciences positions in Q4 2020 and 13 closed out, a net change of +2 holders.
- The largest Forte Biosciences buyer in Q4 2020 was Perceptive Advisors, an estimated $13.2M added.
- The largest Forte Biosciences seller in Q4 2020 was OrbiMed, an estimated $9.34M sold.
Based on aggregated 13F filings for Q4 2020.